LACTB and cancer: This is thought to be due to the empirical antibiotic-based treatment commonly used in oncology departments, prolonged hospital stays by cancer patients, and the various resistance mechanisms developed by E. coli, such as enzymatic inactivation through the production of beta-lactamases, target modification, and efflux [31].